Secondary Logo

Journal Logo

November-December 2004 - Volume 27 - Issue 6
pp: 419-479,S1-S65

Anti-Tumor Effect of an Intratumoral Administration of Dendritic Cells in Combination with TS-1, an Oral Fluoropyrimidine Anti-Cancer Drug, and OK-432, a Streptococcal Immunopotentiator: Involvement of Toll-like Receptor 4

Ahmed, Sharif Uddin; Okamoto, Masato; Oshikawa, Tetsuya; More

Journal of Immunotherapy. 27(6):432-441, November-December 2004.

Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine: A Report on Safety and Immunogenicity

Guthmann, Marcelo D.; Bitton, Roberto J.; Carnero, Ariel J. L.; More

Journal of Immunotherapy. 27(6):442-451, November-December 2004.

Adoptive Immunotherapy


Antibody Therapy

Cancer Biometrics


Addition of Histamine to IL-2 Treatment Augments T1 Cell-Funktion in Melanoma Patients In Vivo: Results from a Randomized Clinical Trial of IL-2 with or without Histamine (MP 104)

Asemissen, Anne Marie; Scheibenbogen, Carmen; Letsch, Anne; More

Journal of Immunotherapy. 27(6):S13, November-December 2004.

Anti-Angiogenic Drugs Syngerize with a Membrane Macrophage Colony Stimulating Factor Based Tumor Vaccine to Therapeutically Treat Rats with an Established Malignant Intracranial Glioma

Jeffes, Edward; Wepsic, Terry; Obenaus, Andy; More

Journal of Immunotherapy. 27(6):S14-S15, November-December 2004.

Interleukin-27 Enhances Tumor Cell MHC Class I Expression and Specific T Cell Reactivity and Mediates CD8+ T-Cell Dependent Regression of Primary and/or Metastatic Murine Neuroblastoma Tumors

Salcedo, Rosalba; Hahn, Cynthia; Stauffer, Jimmy; More

Journal of Immunotherapy. 27(6):S17, November-December 2004.

Cytokine Based Immunotherapy

Dendritic Cells and Vaccines